Serum AFP levels were assessed at baseline, every 4 weeks during treatment, and at the end of treatment. Patients who had a baseline AFP ≥20 ng/mL and an AFP measurement at the start of Cycle 3 were evaluable for AFP response, defined as a decrease of ≥ 20% in AFP level from baseline at the start of Cycle 3....In this exploratory analysis of RESORCE, an AFP response with regorafenib was associated with improved OS.

The median overall survival (OS) with regorafenib was 12.4 months (95% CI, 7.8-17.0) and the median progression-free survival (PFS) was 4.2 months (95% CI, 3.7-4.7)…Patients possessing baseline AFP < 400 ng/ml exhibited a markedly longer median OS, median PFS, and higher DCR compared with their counterparts...The results of this real-world study verified the tolerability and efficacy of regorafenib treatment for uHCC patients...

Patients with on-treatment AFP response (n=196, 34%) had significantly longer OS and PFS than those without AFP response….Baseline AFP and on-treatment AFP response were independent prognostic factors for advanced HCC patients treated with regorafenib.